Maurizio Zazzi

Maurizio Zazzi

Siena, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 218 publications

Increased in-hospital mortality in immunocompromised individuals hospitalized with COVID-19 during the global pandemic, a multinational cohort study in the EuCARE project.

Increased in-hospital mortality in immunocompromised individuals hospitalized with COVID-19 during the global pandemic, a multinational cohort study in the EuCARE project.

Journal: The Journal of infectious diseases

Published: March 04, 2026

Efficacy of dolutegravir or bictegravir-containing therapy in a real-life cohort of people with HIV-1 sub-subtype A6.

Efficacy of dolutegravir or bictegravir-containing therapy in a real-life cohort of people with HIV-1 sub-subtype A6.

Journal: AIDS (London, England)

Published: February 17, 2026

HIV-1 Sub-subtype A6 Remains Susceptible to Second-Generation Integrase Inhibitors With Limited Emergence of Resistance in Vitro.

HIV-1 Sub-subtype A6 Remains Susceptible to Second-Generation Integrase Inhibitors With Limited Emergence of Resistance in Vitro.

Journal: Open forum infectious diseases

Published: October 21, 2025

Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencing.

Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencing.

Journal: The Journal of antimicrobial chemotherapy

Published: September 18, 2025

Teropavimab and zinlirvimab sensitivity in people living with multidrug-resistant HIV-1: data from the PRESTIGIO Registry.

Teropavimab and zinlirvimab sensitivity in people living with multidrug-resistant HIV-1: data from the PRESTIGIO Registry.

Journal: Microbiology spectrum

Published: September 11, 2025

Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes.

Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes.

Journal: The Journal of antimicrobial chemotherapy

Published: August 28, 2025

Correction: Biba et al. A Comparison of Sanger Sequencing and Amplicon-Based Next Generation Sequencing Approaches for the Detection of HIV-1 Drug Resistance Mutations. Viruses 2024, 16, 1465.

Correction: Biba et al. A Comparison of Sanger Sequencing and Amplicon-Based Next Generation Sequencing Approaches for the Detection of HIV-1 Drug Resistance Mutations. Viruses 2024, 16, 1465.

Journal: Viruses

Published: July 11, 2025

Time fixes everything, but not always: 10 years of persistent PI mutations in the absence of pharmacological pressure-a case report.

Time fixes everything, but not always: 10 years of persistent PI mutations in the absence of pharmacological pressure-a case report.

Journal: The Journal of antimicrobial chemotherapy

Published: June 27, 2025

Anti-cluster A and anti-p24 antibodies in people with multidrug-resistant HIV: Preliminary observations from the PRESTIGIO registry.

Anti-cluster A and anti-p24 antibodies in people with multidrug-resistant HIV: Preliminary observations from the PRESTIGIO registry.

Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

Published: June 15, 2025

96-week real-world effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in HIV-infected adults with pre-existing NRTI resistance: A retrospective cohort study.

96-week real-world effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in HIV-infected adults with pre-existing NRTI resistance: A retrospective cohort study.

Journal: Journal of global antimicrobial resistance

Published: June 13, 2025

Comparison of diagnostic performances of HDV-RNA quantification assays used in clinical practice: Results from a national quality control multicenter study.

Comparison of diagnostic performances of HDV-RNA quantification assays used in clinical practice: Results from a national quality control multicenter study.

Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

Published: May 29, 2025

Analysis of the SARS-CoV-2 inactivation mechanism using violet-blue light (405 nm).

Analysis of the SARS-CoV-2 inactivation mechanism using violet-blue light (405 nm).

Journal: Applied and environmental microbiology

Published: May 14, 2025

Showing 1-12 of 218

Last Updated: 09/26/2026